

Exhibit 91

United States of America ex rel. Ven-a-Care of the Florida Keys, Inc. v. Boehringer Ingelheim Corp. et al.

Civil Action No. 07-10248-PBS

Exhibit to the August 28, 2009 Declaration of James J. Fauci In Opposition To
Corrected Boehringer Ingelheim Corporation and Boehringer Ingelheim Pharmaceuticals, Inc.
Local Rule 56.1 Statement of Undisputed Material Facts
in Support of Their Motion For Summary Judgment

Memo

ABCD

To:
S. Berkle
W. Gerstenberg

C. Ferrara
Telephone 203-798-5562
Telefax 203-798-4407

{ DATE \@
"MMMM d, yyyy" *
MERGEFORMAT }

Recommended BIPI/RLI Price Increases for Q1 2002

Boehringer Ingelheim
Corporation

The PTC Committee recommends that we initiate a January 3, 2002 unannounced price increase on most BIPI and RLI Branded Productions.

Please review the attached recommendation, which lists price increases by product, by Company.

The aggregate January 2002 PTC recommended price increase for BIPI (including Torecan and Cafcit) is 4.1% versus the budgeted January 2002 increase of 3.0%.

Please approve by signing below by December 11 so that we may proceed with the proposed increase.

S. Berkle	W. Gerstenberg
-----------	----------------

Thank you,

Chris Ferrara

Director, Forecasting and Sales Support

ABCD

PTC Committee recommended January 3, 2002 price increases.

BIPI Products	January 2002 Recommended Increase	Total 2001 Price Increases
Aggrenox	6.0%	8.1%
Atrovent MDI	4.0%	10.2%
Catapres TTS	3.0%	7.1%
Combivent	6.0%	10.2%
Flomax	0.0%	8.1%
Micardis		
20mg	3.0%	3.0%
40mg	3.0%	3.0%
80mg	5.0%	8.0%
40mg HCT	5.0%	2.0%
80mg HCT	6.0%	2.0%
Mobic		
7.5mg	8.0%	4.0%
15mg	7.0%	4.0%
Viramune	5.4%	9.1%
All Others	3.0%	various

RLI Branded Products	January 2002 Recommended Increase	Total 2001 Price Increases
Cafcit	3.0%	0.0%
Torecan	3.0%	3.5%